SCHEMBL22465645

SCHEMBL22465645

CCCCCC(C=CC(=O)OCC)CCCCC

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 4/20 0.46
ATM Q13315 1/20 0.46
MAPT P10636 2/20 0.42
ZDHHC7 Q9NXF8 1/20 0.40
ALDH1A1 P00352 1/20 0.38
TRPA1 O75762 1/20 0.37
DDAH1 O94760 1/20 0.37
GAPDH P04406 1/20 0.37
CA1 P00915 2/20 0.37
CA12 O43570 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
GPR84 Q9NQS5 3/20 0.36
NPSR1 Q6W5P4 1/20 0.36
FFAR1 O14842 1/20 0.36
FAAH O00519 2/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22627138 1.00 HCAR2 (0.46) HCAR2ATMMAPTZDHHC7ALDH1A1
SCHEMBL21694608 0.98 HCAR2 (0.45) HCAR2ATMMAPTZDHHC7ALDH1A1
SCHEMBL18723218 0.98 HCAR2 (0.45) HCAR2ATMMAPTZDHHC7ALDH1A1
SCHEMBL30914719 0.98 HCAR2 (0.45) HCAR2ATMMAPTZDHHC7ALDH1A1
SCHEMBL25808263 0.97 HCAR2 (0.44) HCAR2ATMMAPTZDHHC7CA2
SCHEMBL6476703 0.88 TSHR (0.46) HCAR2ATMMAPTALDH1A1CA1
SCHEMBL6476706 0.88 TSHR (0.46) HCAR2ATMMAPTALDH1A1CA1
SCHEMBL30914726 0.85 ACHE (0.43) HCAR2ATMMAPTZDHHC7CA2
SCHEMBL29001105 0.83 TRPA1 (0.50) HCAR2ATMMAPTTRPA1DDAH1
SCHEMBL22005512 0.82 ZDHHC7 (0.47) HCAR2MAPTZDHHC7CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260060926-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SAIL BIOMEDICINES INC (US) 2026-03-05 US disclosed
EP-4581012-A2 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME Sail Biomedicines, Inc. (US) 2025-07-09 EP disclosed
US-20250051263-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SAIL BIOMEDICINES, INC. 2025-02-13 US disclosed
US-20250049948-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SAIL BIOMEDICINES, INC. 2025-02-13 US disclosed
CN-118829625-A Novel ionizable lipids and lipid nanoparticles and methods of use thereof 赛欧生物医药股份有限公司 2024-10-22 CN disclosed
EP-4436549-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME Sail Biomedicines, Inc. (US) 2024-10-02 EP disclosed
EP-4433450-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME Sail Biomedicines, Inc. (US) 2024-09-25 EP disclosed
WO-2024049979-A2 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SENDA BIOSCIENCES, INC. (US) 2024-03-07 WO disclosed
WO-2023091787-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SENDA BIOSCIENCES, INC. (US) 2023-05-25 WO disclosed
WO-2023091490-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SENDA BIOSCIENCES, INC. (US) 2023-05-25 WO disclosed
EP-3733647-B1 CATIONIC LIPID EISAI R&D MAN CO LTD (JP) 2022-06-15 EP disclosed
US-10947193-B2 Cationic lipid EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-03-16 US disclosed
EP-3733647-A1 CATIONIC LIPID Eisai R&D Management Co., Ltd. (JP) 2020-11-04 EP disclosed
US-20200308111-A1 Cationic Lipid EISAI R&D MANAGEMENT CO., LTD. (JP) 2020-10-01 US disclosed
CN-111417621-A Cationic lipids 卫材R&D管理有限公司 2020-07-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200308111-A1 Cationic Lipid NPC1L1, NPC1, LPCAT1 HCAR2 2182/4885ATM 4729/4885MAPT 4096/4885
US-20250051263-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME NPC1L1, ABCB4, LIPA HCAR2 3543/4885ATM 3868/4885MAPT 2110/4885
US-20260060926-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SGMS1, NPC1L1, SGMS2 HCAR2 2702/4885ATM 3641/4885MAPT 3365/4885
US-10947193-B2 Cationic lipid NPC1L1, NPC1, LPCAT1 HCAR2 2182/4885ATM 4729/4885MAPT 4096/4885
US-20250049948-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME NPC1L1, ABCB4, LIPA HCAR2 3543/4885ATM 3868/4885MAPT 2110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.